CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D053120: Respiratory Aspiration NIH

(Synonyms: Respiratory As, Respiratory Aspirat, Respiratory Aspiration)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug594 PSG Wiki 0.71
drug597 PUL-042 Inhalation Solution Wiki 0.50
drug616 Placebo Wiki 0.07

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

Adults who have tested positive for SARS-CoV-2 infection and who do not require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome

NCT04312997 COVID-19 Drug: PUL-042 Inhalation Solution Drug: Placebo
MeSH:Infection Respiratory Aspiration

Primary Outcomes

Description: To determine the efficacy of PUL-042 Inhalation Solution in decreasing the severity of COVID-19 in subjects: 1) who have documented SARS-CoV-2 infection and, 2) who do not require supplemental oxygen (Ordinal Scale for Clinical Improvement 3 or less) at the time of enrollment. The primary endpoint is the severity of COVID-19 as measured by the maximum difference from the baseline value in the Ordinal Scale for Clinical Improvement within 10 days from the start of the experimental therapy.

Measure: Severity of COVID-19

Time: 10 days

Secondary Outcomes

Description: SARS-Co-V-2 positivity up to 28 days from the start of experimental therapy

Measure: SARS-CoV-2 infection

Time: 28 days

Description: The severity of COVID-19 as measured by the maximum difference from the baseline value in the Ordinal Scale for Clinical Improvement within 28 days from the start of the experimental therapy.

Measure: Severity of COVID-19 over 28 days

Time: 28 days

Description: The requirement for ICU admission within 28 days from the start of the experimental therapy.

Measure: ICU admission

Time: 28 days

Description: The requirement for mechanical ventilation within 28 days from the start of the experimental therapy.

Measure: Mechanical Ventilation

Time: 28 days

Description: All cause mortality at 28 days from the start of experimental therapy

Measure: Mortality

Time: 28 days

2 Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS

Most patients in intensive care units (ICUs) experience severe sleep disruption. Sleep disruption and sleep alteration may have an influence on the ability to breathe spontaneously. But, the cause of altered sleep remains unknown. Previous studies have shown that decreasing nocturnal respiratory muscle activity through mechanical ventilation might improve sleep quality. Nocturnal respiratory muscle activity may be one of the potential factor which contribute to alter sleep in the ICU. Therefore, the aim of this study is to analyse the presence of NIM activation during the night and it's consequence in an ICU population with the same pathology (COVID 19 ARDS).

NCT04371029 ARDS COVID-19 Other: PSG
MeSH:Respiratory Aspiration

Primary Outcomes

Description: Comparison between patients with NIM activation during the night and patients without NIM activation during the night, in patients COVID 19 ARDS with altered spleep. A Polysomnography (PSG) will be performed the night before extubation.

Measure: Proportion of patients with altered spleep

Time: At day 10 after inclusion

Secondary Outcomes

Description: Thanks to a PSG the night befor discharge, the seep architecture will be estimated.

Measure: Sleep architecture at hospital discharge

Time: At day 28 after inclusion

Description: Thanks to actimetry measure during hospitalization in the post ICU ward.

Measure: Sleep monitoring during hospital stay after ICU discharge

Time: At day 18 after ICU discharge

Description: Sleep quality will be evaluate by the Pittsburgh sleep quality index. The 7 components of the score add up for give an overall score ranging from 0 to 21 points, 0 meaning that there is no difficulty, and 21 indicating on the contrary major difficulties.

Measure: Sleep quality

Time: 3 months after hospiotal discharge

Description: Thanks to a PSG at 3 months, the seep architecture will be estimated.

Measure: Sleep architecture at month-3

Time: 3 months after hospital discharge

Description: all cost will be estimated during ICU hospitalization.

Measure: Cost of ICU hospitalization

Time: From inclusion to ICU discharge, up to 10 days after inclusion


HPO Nodes